ImmunotherapyPhase 3 trialInvestigational
Durvalumab + tremelimumab
Generic name: durvalumab, tremelimumab
How it works
Durvalumab and tremelimumab work together to stimulate the immune system to attack cancer cells.
Cancer types
Pancreatic Cancer— All patients
Efficacy
In clinical trials, the combination of durvalumab and tremelimumab showed promise in improving overall survival in patients with pancreatic cancer, with a median overall survival of approximately 10.8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.